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ABSTRACT
Introduction Several European studies suggest that 
some patients with appendicitis can be treated safely 
with antibiotics. A portion of patients eventually undergo 
appendectomy within a year, with 10%–15% failing 
to respond in the initial period and a similar additional 
proportion with suspected recurrent episodes requiring 
appendectomy. Nearly all patients with appendicitis 
in the USA are still treated with surgery. A rigorous 
comparative effectiveness trial in the USA that is 
sufficiently large and pragmatic to incorporate usual 
variations in care and measures the patient experience 
is needed to determine whether antibiotics are as good 
as appendectomy.
Objectives The Comparing Outcomes of Antibiotic Drugs 
and Appendectomy (CODA) trial for acute appendicitis aims 
to determine whether the antibiotic treatment strategy is 
non-inferior to appendectomy.
Methods/Analysis CODA is a randomised, pragmatic 
non-inferiority trial that aims to recruit 1552 English-
speaking and Spanish-speaking adults with imaging-
confirmed appendicitis. Participants are randomised to 
appendectomy or 10 days of antibiotics (including an 
option for complete outpatient therapy). A total of 500 
patients who decline randomisation but consent to follow-
up will be included in a parallel observational cohort. 
The primary analytic outcome is quality of life (measured 
by the EuroQol five dimension index) at 4 weeks. 
Clinical adverse events, rate of eventual appendectomy, 
decisional regret, return to work/school, work productivity 
and healthcare utilisation will be compared. Planned 
exploratory analyses will identify subpopulations that may 
have a differential risk of eventual appendectomy in the 
antibiotic treatment arm.
Ethics and dissemination This trial was approved by 
the University of Washington’s Human Subjects Division. 
Results from this trial will be presented in international 
conferences and published in peer-reviewed journals.
Trial registration number NCT02800785.
InTROduCTIOn
Acute appendicitis is the most common reason 
for an urgent abdominal operation, with a 
lifetime incidence of 7%–15%.1 Each year, 
nearly 300 000 Americans are hospitalised 
for appendicitis at a cost of US$7.8 billion.2 3 
While appendectomy has been the treatment 
of choice for 120 years, the successful use of 
antibiotics was reported both in a series of 
over 500 patients treated with streptomycin 
in the 1950s and later in submariners who 
did not have access to surgical teams.4 5 As 
anaesthesia and surgical safety improved 
throughout the 20th century, the antibiotics 
treatment strategy was relegated to patients 
with disease severe enough (eg, phlegmon at 
the cecum, abscess) that surgeons felt there 
was a higher risk for surgical complications or 
the need for a more extensive procedure.
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Protocol
Strengths and limitations of this study
 ► This trial will evaluate the comparative effectiveness 
of antibiotics and appendectomy for appendicitis 
based on a comprehensive assessment of impact, 
including the full range of clinical outcomes and 
patient-reported outcomes that matter most to 
patients.
 ► This pragmatic trial was designed to account for the 
diverse aspects of the population, practice settings 
and practices in the USA.
 ► This study builds on the successful experience of 
clinicians to manage patients with potentially serious 
infections as outpatients using risk stratification and 
long-acting parenteral antibiotics.
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Based on these successes with an antibiotic strategy, 
in the 1990s, European investigators began challenging 
the notion that surgery was the best approach to treat 
acute ‘uncomplicated’ appendicitis with a series of 
randomised trials comparing antibiotics and appendec-
tomy.4 6–10 A recent meta-analysis of six randomised trials 
including 1724 randomised adult patients concluded 
that there was a high level of efficacy (91% success in 
the short term with 71% appendectomy-free by 1 year), 
less pain and a quicker return to work in the antibiotic 
arm.11 The largest, most rigorous and recent trial found a 
lower rate of postinterventional complications (reported 
as clinical wound infections, incisional hernia, abdom-
inal pain or obstructive symptoms) in the antibiotics 
group requiring intervention when compared with those 
having open surgical procedures.12 However, in addition 
to the potential for recurrence of appendicitis, a small 
proportion of patients treated with antibiotics likely had 
a neoplasm that would have been incidentally identified 
had they undergone appendectomy. A recent meta-anal-
ysis reported incidental appendiceal neoplasm in 5 of 843 
(0.59%) patients undergoing surgery.11 The meta-anal-
ysis overall concluded that laparoscopic appendectomy 
remains the usual treatment for appendicitis and there 
is a ‘poor evidence base overall with numerous areas of 
bias’, limiting the use of the data for decision making.
The limitations of the existing data regarding antibi-
otics as a primary treatment for acute appendicitis have 
been systematically reviewed.13 Most studies had small 
sample sizes; several did not have standardised imaging 
for diagnosing appendicitis, leading to inclusion of 
patients who likely had ‘complicated’ appendicitis and 
patients without appendicitis; inexact and subjective 
outcome definitions and operation/reoperation criteria 
were used; there were limited or no laparoscopic options 
for surgery and, in some cases, inadequate antibiotic regi-
mens allowed; and most had short follow-up (no studies 
reported following patients beyond 1 year).13 While some 
studies evaluated outcomes including general pain scores 
and use of narcotic pain medication, no study used a vali-
dated patient-reported outcome (PRO) tool to measure 
the patient’s experience in a standardised fashion. Other 
important outcomes to patients such as impact on work 
and school productivity, lingering symptoms, decisional 
regret and healthcare burden (such as emergency room 
care or future imaging) were not included in prior 
studies. Furthermore, prior studies regimented care in 
ways that are not consistent with care in the USA, such as 
requiring several days of inhospital convalescence. These 
limitations may explain the infrequent use of antibiotics 
as the primary treatment for appendicitis in the USA.14
In addition to the need to address these limitations, 
there are additional, unresolved questions that make a 
larger, more definitive study of this treatment question 
important. First, there may be important subgroups of 
people with acute appendicitis who experience the treat-
ment differentially. These might include older patients, 
who are at higher risk for surgical complications, those 
with possible appendiceal perforation detected on 
imaging or those with an appendicolith. The association 
between appendicolith and worse outcomes with antibi-
otics is unclear. Appendicoliths are found in up to 20% of 
appendicitis cases; a similar proportion is also described 
in autopsy studies of normal appendices.15 In several 
paediatric studies and at least one adult study, appen-
dicolith seemed to be associated with eventual appen-
dectomy; however, since many trials did not include 
standardised imaging or criteria for requiring appen-
dectomy following antibiotic therapy for appendicitis, it 
is unclear if the presence of an appendicolith actually 
confers a greater risk.16 17 There is currently no standard 
definition of ‘complicated’ disease. In the USA, usual 
care for appendiceal abscess or phlegmon (inflammation 
so significant that surgeons are concerned for associated 
surgical morbidity) is antibiotics with consideration for 
interval appendectomy. Optimal treatment strategies for 
preoperative radiographic findings of appendiceal perfo-
ration are an area of controversy. The use of radiologic 
imaging to accurately determine perforation is limited; 
in prior randomised trials, patients with perforation were 
likely to have been inadvertently included due to a lack 
of imaging.18 Finally, the European studies mandated the 
use of inpatient antibiotics at a time when there was a 
growing use of outpatient antibiotic regimens for similar 
conditions, such as acute diverticulitis.19–21 A recently 
completed, pilot randomised trial in the USA found that 
14 of 15 adults randomised to antibiotics could success-
fully be discharged from the emergency department (ED) 
and receive all their care as outpatients, resolving their 
symptoms of acute appendicitis.22 One of the remaining 
questions is whether this total outpatient approach to 
antibiotics would be as good as appendectomy in usual 
practice.
Given these evidence gaps it remains to be determined 
if, from the patient’s perspective, the antibiotic treatment 
approach is similar, definitively not worse, and perhaps 
even superior than the standard treatment of appendec-
tomy. The Comparing Outcomes of Antibiotic Drugs and 
Appendectomy (CODA) trial was designed to address 
this question and inform decision-making, focusing on 
commonly used surgical strategies and a range of antibi-
otic strategies, including total outpatient therapy, across 
a broad range of practice environments and a heteroge-
neous group of patients. These questions provide strong 
motivation for a pragmatic trial of antibiotics for acute 
appendicitis.
TRIAl dESIgn
Stakeholder input in design, informed consent and protocol
A central feature of the CODA trial is its engagement 
of stakeholders in study conception, design, and imple-
mentation of the trial.23 The Stakeholder Coordinating 
Center (SCC), established as a formal core within the 
study infrastructure, facilitates all engagement activi-
ties. The SCC engages representatives from the patient 
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population of interest (those at risk for or who have had 
appendicitis), clinicians who are involved in appendicitis 
treatment (including emergency physicians, nurses and 
surgeons), leaders of professional societies (American 
College of Surgeons and American College of Emergency 
Physicians), representatives of Accountable Care Organi-
zations, policy-makers, insurers and payers, researchers 
and leaders from large self-insured employers. Specific 
areas of protocol development informed by SCC included 
selecting primary and secondary outcomes. In addition 
to the routine clinical metrics that are assessed in any 
study of appendicitis treatment, other outcome measures 
important to patients (anxiety, quality of life (QoL), time 
away from work, out-of-pocket expenses) and employers 
(time away from work and productivity at work) were 
included. Stakeholder input was particularly helpful 
in determining the primary analytic outcome, helping 
weigh the prior evidence showing no difference in rates 
of complications with an outcome metric that would ‘sum 
up’ the impact of both treatments on the care experience 
of patients.
Because appendectomy was considered the standard 
and nearly universal therapy in the USA, advisors recom-
mended a study that considered the non-inferiority of 
the antibiotics-first strategy. As one advisor said, ‘the 
burden of proof is on the antibiotics treatment approach 
to demonstrate that it is as good as appendectomy’ (or 
not inferior by more than a small margin). Advisors also 
favoured a non-inferiority framework because the larger 
size required for this design would also allow for multiple 
planned subgroup analyses for patient groups of interest 
and the possibility that superiority of the PRO measure 
might be demonstrated. Lastly, advisors suggested a 
parallel observational cohort to assess for potential selec-
tion bias for patients who declined randomisation.
Patient advisors with an experience of incidentally 
identified neoplasm at the time of appendectomy helped 
modify the inclusion criteria (excluding all patients with 
suggestion of mass of the appendix on imaging) and 
consent form (adding language to make sure that patients 
were informed about this risk, estimated to be 0.6%) and 
directed a change in the protocol (those with lingering 
symptoms in the antibiotics group would be directed to 
follow-up visits and usual care diagnostic evaluations to 
rule out a neoplasm).
Study aims and hypothesis
The aims of the study are to compare PROs and clinical 
outcomes in patients randomised to antibiotics or appen-
dectomy. We hypothesise that antibiotics are non-inferior 
to appendectomy for PROs and that there are subgroups 
with better outcomes (clinical and patient reported) 
with either treatment. A second set of aims is to perform 
subpopulation analyses for patients with appendicolith 
and imaging correlates that may indicate higher risk of 
requiring appendectomy following initiation of antibi-
otic therapy, advanced age, sex, comorbid conditions and 
insurance status.
Study population
The study population includes consecutively presenting 
English-speaking or Spanish-speaking adults (age ≥18 
years) with clinically suspected and imaging-confirmed 
acute appendicitis who present at study site hospital EDs 
in several states.
Exclusion criteria
 ► Inability to participate in follow-up (ie, incarcerated, 
travel without access to phone, email)
 ► Contraindication to one of the study treatment arms:
 – Septic shock (evidence of severe sepsis or septic 
shock includes new presumed sepsis-related 
organ dysfunction, elevated lactate and/or fluid 
unresponsive hypotension)
 – Phlegmon for which surgery would not be 
recommended or diffuse peritonitis for which 
antibiotics alone would not be recommended
 – Imaging findings of walled off abscess and/or free 
air
 – Appendiceal soft-tissue mass concerning for 
malignancy
 ► Other conditions precluding study involvement:
 – Uncompensated liver failure
 – Inflammatory bowel disease requiring active 
medical treatment (eg, Crohn’s, ulcerative colitis)
 – Pregnancy or expectation of becoming pregnant in 
the 30 days following baseline/screening.
 – Surgical implant (eg, left ventricular assist device, 
peritoneal dialysis)
 – Malignancy requiring active treatment 
(eg, chemotherapy)
 – Immunodeficiency (eg, AIDS)
 – Another infection currently treated with systemic 
antibiotics
 – Concurrent illness that would otherwise mandate 
inpatient hospitalisation
 – Severe allergy or reaction to all proposed antibiotics
 – Abdominal or pelvic surgery in the past 30 days.
Of note, patients with radiologic diagnosis of appen-
dicolith and/or imaging concerning for appendiceal 
perforation or phlegmon are included if they do not meet 
the above exclusion criteria and are otherwise eligible.
Recruitment
All patients presenting to the ED with concern for 
appendicitis are screened by study coordinators (7 days 
a week, at least 18 hours per day) based on alerts from 
clinicians, staff and screening of ED logs. Patients are 
identified as potential study candidates based on eligi-
bility criteria collected as part of standard care, including 
confirmatory diagnostic imaging (CT, ultrasound and/
or MRI). A research coordinator and a representative 
from the clinical team confirm the patient’s eligibility 
for the study. A research team member approaches 
all eligible patients and invites them to view a less than 
10 min standardised informed decision-making video 
providing standard information about appendicitis and 
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Table 1 Participant assessment schedule
Item Baseline
Follow-up time point
First 4 weeks Month
1 2 4 3 6 9 12 18 24
Participant point of 
contact
Site RT Site RT Survey centre
Contact information x x x x x x x x x x
EQ-5D42 x x x x x x x x
10-PROMIS Global Health 
short form43
x x x x x x
PROMIS Pain Intensity x x x
Symptom onset x
Additional demographics* x
Treatment satisfaction/
expectation
x x x†
Gastrointestinal Quality of 
Life Index44
x x x x x
Healthcare utilisation x x x x x x x x x
Signs and symptoms of 
appendicitis
x x x x x x x x x
Adverse events x x x x x x x x x
Decision Regret Scale45 x x x
Major life changes x x x x x x x
Work Productivity Index x x x x
Return to work 
information
x x x x†
Medication use x x x x†
Treatment strategy 
change
x x x
*Includes the following topics: demographics and gender identity, caregiver role, instrumental support, employment/student status, income, 
pain catastrophising, health literacy, social support, confidence in treatment success and trust in healthcare.
†Only asked if the 1-month results have not normalised.
EQ-5D, EuroQol five dimension; PROMIS, patient-reported outcomes measurement information system; RT, research team.
the different treatment options (offered in English and 
Spanish versions, https://www. youtube. com/ playlist? list= 
PLQUQ6jdR0MPaq- a8CvSdhVwnuYzNKF9tu).
Participants who decline randomisation are asked 
to participate in the observational cohort (with similar 
baseline and follow-up measures as participants in the 
randomised controlled trial). All patients are asked for 
permission to be followed through passive electronic 
medical record (EMR) review.
Participant follow-up assessment
Participants are contacted 24–48 hours after discharge 
by a member of the research team to answer any ques-
tions about the study and review the survey protocol 
(see table 1). Participants are then contacted by phone by 
site research coordinators 1 and 2 weeks after enrolment 
for study assessments. Data collected through the 2-week 
assessment are entered by site research coordinators into 
a REDCap database, which is managed by the University 
of Washington (UW) data coordinating centre (DCC).24 
Starting with the week 4 assessment, corresponding 
to our primary endpoint assessment, participants are 
contacted by phone, mail or email by the UW Survey 
Center to complete the remaining study assessments (at 
3, 6, 9, 12, 18 and 24 month surveys). The UW Survey 
Center uses the DatStat survey platform (DatStat, Seattle, 
Washington, USA) to create individualised outreach plans 
that optimise survey completion rates. Outreach methods 
are modified to accommodate a participant’s preferred 
mode of contact (email, mail, phone) as well as time of 
day for contact (if by phone). If a participant requests to 
speak with a medical provider or has concerning medical 
symptoms reported to the research team, the clinical 
team via the surgical site lead is contacted to call the 
participant for further follow-up.
The DCC performs early quality assurance checks by 
running REDCap data quality reports. These reports iden-
tify missing values for required fields, incorrect data type, 
range checks, outliers, hidden fields that contain values 
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Table 2 Statistical power to declare non-inferiority on 
patient-reported quality of life, overall and by subgroup 
(non-inferiority margin, M=−5%, one-sided alpha=0.025)
Treatment 
difference, 
Δ (%)
Overall (%) Subgroups (%)
n=1552 n=250 n=400 n=500
−3 82.6 – – –
−2 99.4 – 57.1 67.9
−1 100 62.4 83.8 91.4
0 100 83.0 96.4 98.8
and multiple-choice fields with invalid values. Values that 
need to be corrected are brought to the attention of the 
research staff at that site.
Study arms
Antibiotics therapy arm
Patients in the antibiotics treatment arm receive a 
minimum of 24 hours of treatment using an intrave-
nous antibiotic formulation (administered in q8, q12 
or q24 hour regimens) followed by oral antibiotics for 
a total of a 10-day antibiotic course. Patients are offered 
a treatment regimen of antibiotics based on guidelines 
published jointly by the Surgical Infection Society (SIS) 
and the Infectious Disease Society of America (IDSA) for 
intravenous antibiotics25 and oral antibiotics based on in 
vitro activity against aerobic and anaerobic Gram-neg-
ative bacteria, practical experience with oral antibiotic 
regimens used to treat diverticulitis and IDSA/SIS guide-
lines. The first dose of antibiotics is given in the ED at the 
time of diagnosis of appendicitis, and a total outpatient 
regimen of antibiotics is an option for patients meeting 
ED discharge criteria. Antibiotics are procured from the 
pharmacy by the patient as per usual clinical care.
Appendectomy is recommended only if there is 
development of diffuse peritonitis, development of 
septic shock26 and/or worsening signs and symptoms of 
appendicitis after 48 hours. The decision to perform an 
appendectomy in participants randomised to antibiotics 
is made by the treating surgeon after consultation with 
the study clinical research lead to confirm that the above 
criteria have been satisfied.
Standard discharge criteria are applied to those treated 
in the ED and those who are admitted, and the criteria 
include tolerance of liquids, adequate pain control 
and improving clinical condition. All participants are 
contacted at 24–48 hours by the research coordinator to 
review the study protocol for follow-up assessments.
Follow-up with the clinical team is per usual care at each 
institution. Participants in the antibiotics arm who return 
to any of the study sites during the follow-up period with 
recurrent appendicitis are not rerandomised but are 
offered the choice of either appendectomy or another 
antibiotic course, if treating surgeon agrees that their 
recurrence can be treated with either option.
Appendectomy therapy arm
All patients randomised to appendectomy receive preop-
erative antibiotics per hospital standards for surgical infec-
tion prevention protocols. Appendectomy is performed 
by an open or laparoscopic approach, depending on 
patient and surgeon preference.
Blinding and randomisation
This is an unblinded study as patients will know if they 
were randomised to appendectomy or antibiotics. A sepa-
rate DCC at UW generates and maintains randomisation 
lists for each practice site. Using block randomisation 
optimises the chances of equal numbers of subjects being 
randomised to each treatment arm, and that treatment 
is balanced at periodic enrolment intervals. Randomisa-
tion is further stratified by the presence of appendicolith. 
All other subgroups of interest will be sufficiently large 
such that the risk of a meaningful imbalance in treatment 
groups by chance is unlikely. A web-based portal provides 
the randomised treatment assignment.
Outcomes and measures
The primary outcome for the CODA trial is the EuroQol 
five dimension (EQ-5D) index reported 4 weeks after 
randomisation. In addition, important clinical outcomes 
include major complications and resolution of symptoms 
by 4 weeks; eventual appendectomy (due to failure in clin-
ical improvement, progression of disease severity or due 
to recurrent appendicitis), pain, narcotic use, recurrent 
episodes of appendicitis, ED visits for abdominal pain/
repeat imaging, need for more complicated surgical 
procedure including laparoscopic converted to open 
appendectomy and ileocecectomy, rates of perforation 
and rates of future small bowel obstructions and hernia 
development are collected and will be reported through 
2 years. Complications in both treatment groups are 
tracked and adjudicated by an independent safety monitor 
to determine their relation to the disease and treatment. 
Secondary PROs include a measure of decisional regret, 
anxiety, additional QoL measures (PROMIS-Global, 
Gastrointestinal Quality of Life Index), days missed from 
work or school, time in healthcare, measures of caregiver 
burden and out-of-pocket expenses.
Sample size
The sample size was calculated based on the difference in 
EQ-5D between the two treatment interventions (table 2). 
The EQ-5D QoL index ranges from 0 (worst QoL) to 
1 (highest QoL), where anchor-based methods have 
shown that the minimally clinically important difference 
ranges 5%–10%.27 On the basis of data from a prior 
study of appendectomy with EQ-5D scores at 12 weeks,28 
we estimate that the average EQ-5D for the participants 
randomised to appendectomy will be 0.90 with an SD of 
0.12. To assess QoL differences between interventions, a 
total of 1552 patients will be enrolled, assuming a 90% 
follow-up at 4 weeks. This will give the study very high 
power (>99%) to rule out an EQ-5D difference between 
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Figure 1 Example study conclusions in the Comparing 
Outcomes of Antibiotic Drugs and Appendectomy trial. 
There are four possible study conclusions. (A) The observed 
treatment effect (black circle) of antibiotics is almost zero 
and the 97.5% one-sided CI (arrow) does not overlap the 
non-inferiority margin of −5%, indicating that antibiotics is 
a non-interior strategy. (B) The observed treatment effect 
of antibiotics is more than 2.5% better than appendectomy 
and the CI does not include 0, indicating that antibiotics are 
superior. (C) The observed treatment effect of antibiotics 
is 2.5% worse than appendectomy but the CI includes 
−5%, so non-inferiority cannot be claims. (D) The observed 
treatment effect of antibiotics is more than 5% worse than 
appendectomy, indicating that antibiotics are inferior.
groups as small as 5% (if treatment differences of 0%–2% 
are observed) and 80% power if a treatment difference of 
3% is observed.22
On the basis of pilot data and stakeholder engage-
ment, we estimate a randomisation rate of 30% of all 
potential patients. Based on current appendectomy 
volume at the hospitals participating in the trial, recruit-
ment is planned for 3 years with potential for extension 
through 4 years.
Statistical analysis
We will assess the EQ-5D at 4 weeks, using a linear regres-
sion model that adjusts for an indicator of randomised 
treatment group assignment and for all factors used to 
stratify randomisation (ie, recruitment site, presence of 
appendicolith). As recommended by the US Food and 
Drug Administration guidelines on clinical trial design, 
the estimated treatment effect and 97.5% one-sided 
CI will be compared with the non-inferiority margin 
(M=−5%).29–32 We will conclude that antibiotics are non-in-
ferior to appendectomy if the entire 97.5% one-sided CI 
is greater than M, as in example scenario A (figure 1). 
This is equivalent to a one-sided (alpha=0.025) test of the 
null hypothesis H0: Δ<−5%, for which Δ represents the 
difference in mean EQ-5D at 4 weeks comparing antibi-
otics-first to appendectomy-first treatment assignment. If 
the null hypothesis of H0: Δ<−5% is rejected at the final 
evaluation, then we will conduct a test of superiority to 
determine the level of statistical evidence supporting 
an alternative hypothesis HA: Δ>0% (ie, scenario B of 
figure 1).
Important clinical endpoints (30-day major complica-
tions, days until resolution of symptoms, rates of perfo-
rated appendicitis, extent of operation and surgical 
complications, complications associated with antibiotics, 
hospital days, number of days using antibiotics beyond 
the initial treatment, clinic visits and caregiver/patient 
‘time in healthcare’) will also be compared between 
intention-to-treat (ITT) groups using regression models 
appropriate to each endpoint (eg, linear, logistic, Poisson 
or Cox proportional hazards regression models), along 
with a similar non-inferiority framework.
Secondary analyses
We aim to include a heterogeneous population of 
patients and healthcare settings and plan to explore 
differences in treatment outcomes across subgroups of 
interest, including those with appendicolith, people with 
specific imaging findings including possible appendi-
ceal perforation, those in different age groups (18–64 or 
≥65) and sex and those whose outcomes may vary due to 
differences in work and insurance status, comorbidities 
or social support. We will evaluate difference in treatment 
effectiveness based on modality of receipt of antibiotics 
(all outpatient vs inpatient/outpatient). We will sepa-
rately assess treatment effect heterogeneity by adding to 
the primary outcome model an interaction term between 
the categorical subgroup variable of interest and the indi-
cator of treatment. We will use a global likelihood ratio 
test to examine if the treatment effect differs between key 
subgroups of interest.
An ITT approach will be applied in the primary anal-
ysis. We will conduct a secondary as-treated analysis of the 
primary outcome measure that appropriately accounts for 
patient-level or provider-level characteristics found to be 
differentially represented among patients who start in the 
antibiotics arm and who undergo appendectomy before 
24 hours of treatment or patients who are randomised to 
appendectomy but refuse the procedure and continue 
on antibiotics. We will consider a two-stage approach for 
this as-treated analysis: (1) to identify subgroups that are 
likely to require appendectomy and therefore should 
not be considered good candidates for treatment with 
antibiotics as primary treatment strategy and (2) to esti-
mate the complier average causal effect, which seeks to 
compare the outcomes of patients treated successfully 
in the antibiotic treatment arm (ie, did not ultimately 
have surgery) with patients randomised to the appendec-
tomy arm who are similar in their expected compliance 
to assigned treatment.33–35 We will use a maximum-likeli-
hood mixture modelling approach to identify the optimal 
comparison group from the control arm for observed 
compliers in the intervention arm. Secondary analyses 
of the primary outcome measures will include exam-
ining the entire trajectory of EQ-5D QoL measurements 
for each patient using linear mixed-effects models for 
longitudinal data.36 Finally, a composite outcome metric 
(symptom resolution without complication) was used in 
the recently completed pilot trial and will be included 
as an exploratory measure.22 Because the composite 
outcome includes only clinical domains, and is relevant 
to both treatment groups, this may be a helpful measure 
for clinicians considering the two treatments.
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data safety and monitoring
Event reporting
Death, life-threatening events and rehospitalisation (other 
than for treatment of appendicitis) are classified as serious 
adverse events (SAEs). Morbidity events (using modified 
definitions from the National Surgical Quality Improve-
ment Program (NSQIP) to accommodate non-operative 
care) are considered adverse events (AEs). AEs, SAEs 
and appendectomy after starting antibiotic treatment are 
identified through three approaches; EMR review, patient 
surveys and ad hoc reporting by any research or care team 
member. All SAEs are adjudicated by an independent 
safety monitor. SAEs and AEs are reviewed by the data and 
safety monitoring board (DSMB) biannually (with the 
exception of death, which is reported to the DSMB within 
24 hours). An independent DSMB reviews the accruing 
data to (1) ensure that study conduct, enrolment and 
patient follow-up is adequate; (2) ensure that there are 
no serious safety concerns and (3) assess evidence related 
to patient-reported QoL. The analysis of accruing data is 
completed by the DCC, and interim analysis is presented 
to the DSMB with the primary goal of monitoring safety 
outcomes by randomisation group. Interim monitoring 
for SAE and AE will focus on the first 4 weeks of follow-up. 
The DSMB will conduct interim analyses at 12, 24 and 36 
months.
The CODA trial does not include a stopping rule if 
non-inferiority is met before complete accrual or if it is 
determined that non-inferiority cannot be demonstrated 
in interim analyses. We are not employing a stopping 
rule because there are important secondary outcomes 
(eg, rate of eventual appendectomy, complications, 
subgroup analysis) and understudied subgroups that 
require full enrolment.
dISCuSSIOn
Prior trials randomising patients with appendicitis to anti-
biotics compared with appendectomy focused on disease 
cure, with the primary outcome being the rate of appen-
dectomy among antibiotic-treated participants. Previous 
studies of more than 800 participants randomised to 
antibiotics suggested that the treatment did not increase 
the rate of complications and offered as high as a 75% 
chance of avoiding appendectomy within a year.6–9 12 37 
What remains to be evaluated is the comparative effective-
ness of the two candidate treatments based on a compre-
hensive assessment of impact, including the full range of 
clinical outcomes and PROs that matter most to patients. 
CODA’s pragmatic design aims to evaluate antibiotics in a 
heterogeneous population and practice settings in a large 
randomised trial, with a parallel observational cohort to 
assess selection bias. One of the greatest novelties of the 
CODA trial is its patient centredness, demonstrated both 
by the engagement of patients and other stakeholders as 
partners in selecting the topic, designing the proposal, 
developing the protocol and overseeing operations and in 
the selection of a QoL endpoint for the primary analysis.
CODA was designed to directly inform patient and 
clinician decision making in the community, and several 
pragmatic features were added to make sure it accounted 
for the diverse aspects of the population, practice settings 
and practices in the USA. As a pragmatic trial, CODA 
has limited exclusion criteria and incorporates the many 
ways clinical care is delivered across sites of practice. The 
protocol allows patients in either study arm to leave the 
healthcare setting as soon as standard discharge criteria 
are met, including the possibility of completely outpatient 
care. CODA takes place in diverse study sites (academic, 
private, public, community and county hospitals) with 
patients from a wide range of demographic and socio-
economic characteristics, including both Spanish and 
English speakers. This enhances the generalisability of the 
findings, but may compromise study fidelity if patients in 
any one group have differential treatment preferences or 
prove more difficult to contact for follow-up. A downside 
to this approach is that, by including nearly all patients 
with appendicitis (including those with appendicolith 
and radiographic findings of perforation who may be at 
higher risk for requiring an appendectomy) and those 
undergoing total outpatient antibiotics (which clinicians 
have less experience with), there is a risk of subgroups 
with very different outcomes from the broader popula-
tion and a skewing of the average study results. Using 
Thorpe’s PRagmatic-Explanatory Continuum Indicator 
Summary rubric for pragmatic trials, the proposed study 
is considered highly pragmatic, intended to improve the 
generalisation and precision of decision-making beyond 
the prior randomised studies.38
The results from the European trials of antibiotics 
have not significantly changed care delivery in the USA 
and have been met with resistance, in part due to the 
evidence gaps cited earlier and concern about the fate of 
patients with recurrent disease.39 American patients may 
also have different expectations and resources that influ-
ence perception of treatment success and satisfaction 
with treatments. One particular protocol component of 
the European trials that may make them less applicable 
to the US experience is that prior studies all required an 
inhospital convalescence for a fixed period of time for 
both treatment arms that is double the length of stay that 
the average US patient experiences. CODA builds on the 
successful experience of emergency medicine clinicians 
to manage patients with potentially serious infections 
as outpatients using risk stratification and long-acting 
parenteral antibiotics (eg, diverticulitis), and its effective-
ness will be tested in different practice settings and popu-
lations. This novel treatment alternative offers avoidance 
of hospital admission and may substantially reduce costs 
compared with surgical treatment,
Stakeholder input is a key component of the emerging 
field of patient-centred outcomes research. However, 
including several types of stakeholders (patients, physi-
cians, payers and purchasers) does not always result 
in consensus. The selection of an appropriate analytic 
outcome for the trial was an example. While prior 
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studies focused on clinical outcome (eg, rates of appen-
dectomy and surgical complications), patient advisors 
recognised that these outcome measures are specific 
to only one treatment arm (and to people treated with 
antibiotics who proceed to appendectomy) and that 
standardised measurements of QoL would be appli-
cable to both and had yet to be rigorously assessed. The 
EQ-5D has been used in prior studies of appendectomy, 
but never in comparisons of these two treatments.28 
Using the EQ-5D as a primary outcome measure was 
highly relevant to many, but not all, patients. There is 
a possibility that the primary analytic outcome analysis 
(non-inferiority of the EQ-5D) could be positive, but 
other outcome domains might not be aligned. For this 
reason, multiple secondary analyses and exploratory 
endpoints have been selected a priori. Evidence in the 
field of decision-making suggests that patients want 
information on multiple domains, but we recognise 
that multiple outcome domains may also add confu-
sion to interpretation of results and implementation in 
future practice.
As in all trials, patients are not required to stay in the 
treatment arms they are assigned to (non-adherence 
or crossover); for example, select patients in the anti-
biotics arm might not be willing to receive 24 hours of 
antibiotics and opt for an appendectomy despite not 
meeting clinical trial protocol recommendations or 
patients randomised to appendectomy might refuse 
surgery. While the main analytic approach is an ITT 
framework, careful as-treated and secondary data anal-
yses may be helpful in accounting for such non-adher-
ence/crossover.40 Detry and Lewis recommend both an 
ITT and a careful as-treated analysis to address cross-
overs in non-inferiority trials where non-adherence or 
crossover is present.41 A simple as-treated analysis is 
problematic because of potential differences in demo-
graphic or clinical characteristics that introduce bias in 
as-treated group comparisons. Our analytic approach 
proposed involves a two-stage as-treated analysis and 
potentially will yield conclusions that differ from ITT 
analysis. However, the ITT results will be considered the 
primary analysis and are robustly valid since they only 
depend on randomisation and do not depend on model 
assumptions required for observational comparisons.41
CODA began recruitment in the summer/fall of 2016 
with eight hospitals in Washington and California with 
additional hospitals across the United States planned 
to begin recruitment in 2017. It is possible that not 
all clinical sites will continue to contribute patients 
throughout the entire recruitment period (projected to 
be 3–4 years). Substudies and ancillary studies are being 
proposed to focus on biomarkers, economic analysis, 
longer-term results and other predictors of outcome.
In conclusion, the CODA trial was designed to 
address critical knowledge gaps related to the treat-
ment of appendicitis with antibiotics compared with 
appendectomy. CODA’s stakeholder-informed design 
and operations, pragmatic design and inclusion of an 
innovative approach to outpatient antibiotics aim to 
inform choices in care for this common condition, 
and planned subgroup analyses allow for improved 
decision making.
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